Contact
searchSearch
HMP Global
Login

Ovarian Cancer

Ovarian Cancer
Specialty Channel
Lucy Gilbert, MD, MSc
Videos
Relacorilant Plus Nab-paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer Regardless of Prior Taxane Use
06/23/2026
Lucy Gilbert, MD, MSc
Lucy Gilbert, MD, MSc, Chair of Oncology at McGill University and Chief of Gynecological Oncology at the McGill University Health Centre, discusses findings from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel versus...
Lucy Gilbert, MD, MSc, Chair of Oncology at McGill University and Chief of Gynecological Oncology at the McGill University Health Centre, discusses findings from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel versus...
Lucy Gilbert, MD, MSc, Chair of...
06/23/2026
Oncology
News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
News
Chiauranib Plus Weekly Paclitaxel Significantly Improves PFS in Platinum-Resistant Ovarian Cancer
05/29/2026
Emily Estrada
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO...
05/29/2026
Oncology
Cara Mathews, MD
Videos
Rinatabart Sesutecan Plus Bevacizumab in Recurrent Ovarian Cancer
05/21/2026
Cara Mathews, MD
Cara Mathews, MD, discusses results from the cohort D2 of the phase 1/2 RAINFOL-01 study assessing rinatabart sesutecan plus bevacizumab in patients with recurrent ovarian cancer.
Cara Mathews, MD, discusses results from the cohort D2 of the phase 1/2 RAINFOL-01 study assessing rinatabart sesutecan plus bevacizumab in patients with recurrent ovarian cancer.
Cara Mathews, MD, discusses...
05/21/2026
Oncology
Alexander Olawaiye, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
05/07/2026
Alexander Olawaiye, MD
Alexander Olawaiye, MD, discusses final overall survival results from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Alexander Olawaiye, MD, discusses final overall survival results from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Alexander Olawaiye, MD,...
05/07/2026
Oncology
Alison Schram, MD
Videos
Rezatapopt Shows Clinical Promise in TP53-Mutated Ovarian Cancer
05/04/2026
Alison Schram, MD
Alison Schram, MD, discusses results from the phase 2 PYNNACLE trial which assessed rezatapopt in TP53 Y220C mutated advanced or metastatic ovarian cancer.
Alison Schram, MD, discusses results from the phase 2 PYNNACLE trial which assessed rezatapopt in TP53 Y220C mutated advanced or metastatic ovarian cancer.
Alison Schram, MD, discusses...
05/04/2026
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer
04/30/2026
Brian Slomovitz, MD
Brian Slomovitz, MD, discusses results from the ROSELA trial which led to the recent FDA approval of relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses results from the ROSELA trial which led to the recent FDA approval of relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
04/30/2026
Oncology
Emese Zsiros, MD, PhD
Videos
Pembrolizumab Plus Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
04/24/2026
Emese Zsiros, MD, PhD
Emese Zsiros, MD, PhD, discusses results from the phase 3 KEYNOTE-B96 trial, which demonstrated that pembrolizumab improves survival while maintaining quality of life in patients with platinum-resistant ovarian cancer.
Emese Zsiros, MD, PhD, discusses results from the phase 3 KEYNOTE-B96 trial, which demonstrated that pembrolizumab improves survival while maintaining quality of life in patients with platinum-resistant ovarian cancer.
Emese Zsiros, MD, PhD, discusses...
04/24/2026
Oncology
News
Mirvetuximab Plus Carboplatin Demonstrates Promise in Platinum-Sensitive Ovarian Cancer
04/21/2026
Stephanie Holland
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2...
04/21/2026
Oncology
News
LB-100 Plus Dostarlimab Shows Clinical Promise in Platinum-Resistant Ovarian Clear Cell Carcinoma
04/15/2026
Emily Estrada
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase...
04/15/2026
Oncology
News
Longitudinal ctDNA Clearance Predicts Outcomes in Advanced Ovarian Cancer
04/15/2026
Emily Estrada
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective...
04/15/2026
Oncology

News

News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
News
Chiauranib Plus Weekly Paclitaxel Significantly Improves PFS in Platinum-Resistant Ovarian Cancer
05/29/2026
Emily Estrada
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO...
05/29/2026
Oncology
News
Mirvetuximab Plus Carboplatin Demonstrates Promise in Platinum-Sensitive Ovarian Cancer
04/21/2026
Stephanie Holland
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2...
04/21/2026
Oncology
News
LB-100 Plus Dostarlimab Shows Clinical Promise in Platinum-Resistant Ovarian Clear Cell Carcinoma
04/15/2026
Emily Estrada
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase...
04/15/2026
Oncology
News
Longitudinal ctDNA Clearance Predicts Outcomes in Advanced Ovarian Cancer
04/15/2026
Emily Estrada
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective...
04/15/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
04/13/2026
Stephanie Holland
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results...
04/13/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology

Interactive Features

Quiz
Front-Line Treatment Options for Ovarian Cancer
12/20/2023
12/20/2023
Oncology
Quiz
New and Emerging Targeted Therapies for Relapsing Ovarian Cancer
11/29/2023
11/29/2023
Oncology
Quiz
Maintenance Olaparib Rechallenge for Ovarian Cancer
10/31/2023
10/31/2023
Oncology
Quiz
Sleeping Beauty Mutagenesis in High-Grade Ovarian Cancer
05/16/2023
How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?
How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?
How is Sleeping Beauty...
05/16/2023
Oncology
Quiz
Quiz: FDA Approves Mirvetuximab Soravtansine
12/15/2022
What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?
What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?
What treatment must patients...
12/15/2022
Oncology
Quiz
Quiz: Hyperthermic Intraperitoneal Chemotherapy Agent of Choice
12/02/2022
What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?
What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?
What is the most prevalent...
12/02/2022
Oncology
Quiz
Quiz: Pafolacianine With Near-Infrared Imaging for Detecting Folate Receptor-Positive Ovarian Cancer
11/03/2022
A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?
A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?
A phase 3 open-label study found...
11/03/2022
Oncology
Quiz
Quiz: Promising Novel Therapy in Tough-to-Treat Ovarian Cancer
03/27/2022
True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.
True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.
True or false: Researchers at...
03/27/2022
Oncology
Test Your Knowledge
Quiz: A Common Thread in Rising Endometrial Cases in US Women
05/29/2021
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in...
05/29/2021
Oncology
Test Your Knowledge
Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?
05/28/2021
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings...
05/28/2021
Oncology

Recent News

News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
News
Chiauranib Plus Weekly Paclitaxel Significantly Improves PFS in Platinum-Resistant Ovarian Cancer
05/29/2026
Emily Estrada
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO...
05/29/2026
Oncology
News
Mirvetuximab Plus Carboplatin Demonstrates Promise in Platinum-Sensitive Ovarian Cancer
04/21/2026
Stephanie Holland
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2...
04/21/2026
Oncology
News
LB-100 Plus Dostarlimab Shows Clinical Promise in Platinum-Resistant Ovarian Clear Cell Carcinoma
04/15/2026
Emily Estrada
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase...
04/15/2026
Oncology
News
Longitudinal ctDNA Clearance Predicts Outcomes in Advanced Ovarian Cancer
04/15/2026
Emily Estrada
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective...
04/15/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
04/13/2026
Stephanie Holland
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results...
04/13/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use